Southwest Oncology Group studies in bladder cancer

E. David Crawford, David P. Wood, Daniel P. Petrylak, Jennifer Scott, Charles A. Coltman, Derek Raghavan

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Over 50,000 patients are diagnosed annually with bladder cancer, and approximately 10,000 eventually will die of their disease. Thus, the Southwest Oncology Group (SWOG) Genitourinary Cancer Committee is committed to the study of therapeutic interventions in patients with superficial, invasive, and metastatic bladder cancer. In the past 15 years, SWOG has completed six Phase III, randomized trials. Studies in patients with superficial disease have established the role of bacillus Calmette-Guerin in patient management; and a large, randomized trial has outlined the value of neoadjuvant chemotherapy and cystectomy in patients with advanced disease. SWOG plans to build on this model by evaluating patients with residual disease after chemotherapy for possible bladder preservation while evaluating more chemotherapy for patients with persistent disease. The Genitourinary Cancer Committee will continue to seek new, active agents for metastatic disease and will participate in and support large, Phase III, international trials that seek to improve current regimens. SWOG accomplishments in bladder cancer are highlighted, and future strategies are discussed.

Original languageEnglish (US)
Pages (from-to)2099-2108
Number of pages10
JournalCancer
Volume97
Issue number8 SUPPL.
DOIs
StatePublished - Apr 15 2003
Externally publishedYes

Keywords

  • Bacillus Calmette-Guerin
  • Phase III trials
  • Superficial bladder cancer
  • Tumor characteristics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Southwest Oncology Group studies in bladder cancer'. Together they form a unique fingerprint.

Cite this